Salenvac T vaccine spreads wings at VIV

23 October 2003

Boxmeer, September 1, 2003 - VIV 2003 is the first non-UK debut of Nobilis Salenvac T, Intervet’s salmonella vaccine that protects against both S.enteritidis and S.typhimurium, making it an important advancement in efforts to make poultry meat and eggs safer for humans. 

Salenvac T is the only vaccine to fight both salmonella strains, the most frequently reported causes of food poisoning in humans. It joins the Nobilis family of safe poultry products, which includes Salenvac and SG 9R. The "T" signifies protection against S.typhimurium, which increasingly concerns the industry. Salenvac T builds on the success of Nobilis Salenvac, an inactivated S.enteritidis vaccine introduced in the UK in 1994 and used effectively worldwide. 

Grown under Iron Restriction-conditions, it produces an immune response that mimics the natural Salmonella challenge. Its aluminium hydroxide adjuvant is safe for birds and people. Research reveals cross protection against other group B and D salmonella strains including S.agona and S.heidelberg. 

Available in the U.K. since January 2003, Salenvac T will be introduced throughout Europe in early 2004. For information, visit the Intervet stand in Hall 3, number A122. 

Further information:

Mr. Ruud Aerdts
mailto: Ruud.Aerdts@intervet.com
Tel: +31 (0)485-587 600 

Note for the editor: 

Intervet, a business unit of Akzo Nobel, headquartered in Boxmeer, The Netherlands, with sales of EUR 1,081 million in 2002, is focused on the research and development, manufacturing and marketing of veterinary products. Products include vaccines for the prevention of infectious diseases, anti-infectives, anti-parasitics, pharmaceutical specialities and products for fertility management. All of these products are intended for use in a variety of animal species, including poultry, pigs, cattle, sheep, goats, horses, fish and companion animals. Intervet operates globally with its own marketing organizations. The company currently employs around 5,000 people. 

Internet: www.intervet.com 

Akzo Nobel, based in the Netherlands, serves customers throughout the world with healthcare products, coatings and chemicals. Consolidated sales for 2002 totaled EUR 14 billion. The Company currently employs approximately 65,200 people in more than 80 countries. Financial results for 2003 will be published on February 3, 2004. 

Internet: www.akzonobel.com